Remicade behind Mitsubishi Tanabe's first-half growth
This article was originally published in Scrip
Remicade (infliximab; licensed from Johnson & Johnson) was again the star performer at Japan's Mitsubishi Tanabe Pharma (MTP) in the first half to 30 September, in which sales of the TNF-targeting antibody rose by 29% to ¥29.3 billion ($364.0 million).
You may also be interested in...
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.